Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
ATP Binding Cassette Transporter, Subfamily B
/ genetics
Adult
Arylamine N-Acetyltransferase
/ genetics
Female
Genotype
Glucuronosyltransferase
/ genetics
Humans
Isoniazid
/ administration & dosage
Liver-Specific Organic Anion Transporter 1
/ genetics
Male
Polymorphism, Single Nucleotide
/ genetics
Recurrence
Rifampin
/ administration & dosage
Tuberculosis
/ drug therapy
isoniazid
pharmacogenetics
pharmacokinetics
pyrazinamide
rifampicin
tuberculosis
Journal
Pharmacogenomics
ISSN: 1744-8042
Titre abrégé: Pharmacogenomics
Pays: England
ID NLM: 100897350
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
16
2
2019
medline:
19
3
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin. Genotypes for SLCO1B1, NAT2, PXR, ABCB1 and UGT1A genes were determined using a TaqMan Among 172 patients, 18, 43 and 34% were classified as rapid, intermediate and slow NAT2 acetylators, respectively. Of the 58 patients contributing drug concentrations, rapid and intermediate acetylators had 2.3- and 1.6-times faster isoniazid clearance than slow acetylators. No association was observed between rifampicin pharmacokinetics and SLCO1B1, ABCB1, UGT1A or PXR genotypes. Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation.
Identifiants
pubmed: 30767706
doi: 10.2217/pgs-2018-0166
pmc: PMC6562923
doi:
Substances chimiques
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Liver-Specific Organic Anion Transporter 1
0
SLCO1B1 protein, human
0
Arylamine N-Acetyltransferase
EC 2.3.1.5
NAT2 protein, human
EC 2.3.1.5
UGT1A1 enzyme
EC 2.4.1.-
Glucuronosyltransferase
EC 2.4.1.17
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Banques de données
ClinicalTrials.gov
['NCT02114684']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-240Subventions
Organisme : Wellcome Trust
ID : 206379/Z/17/Z
Pays : United Kingdom
Références
J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):473-505
pubmed: 12795242
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Eur J Clin Invest. 2003 Nov;33 Suppl 2:1-5
pubmed: 14641549
Pharmacogenomics. 2012 Jan;13(1):31-41
pubmed: 22092036
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):711-26
pubmed: 17653836
Eur J Clin Pharmacol. 2013 May;69(5):1091-101
pubmed: 23150149
Clin Infect Dis. 2012 Jul;55(2):169-77
pubmed: 22467670
Int J Tuberc Lung Dis. 2015 Feb;19(2):210-5
pubmed: 25574921
Pharmacogenet Genomics. 2011 Mar;21(3):152-61
pubmed: 20216335
Clin Infect Dis. 2009 Jun 15;48(12):1685-94
pubmed: 19432554
Clin Infect Dis. 2009 Jun 1;48(11):1547-53
pubmed: 19392636
Pharmacogenet Genomics. 2014 Aug;24(8):409-25
pubmed: 24892773
Drug Des Devel Ther. 2015 Sep 30;9:5433-8
pubmed: 26491254
Antimicrob Agents Chemother. 2015 Jan;59(1):38-45
pubmed: 25313213
Annu Rev Pharmacol Toxicol. 2008;48:303-32
pubmed: 17914927
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28607022
Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3
pubmed: 16480505
Clin Pharmacol Ther. 2015 Oct;98(4):387-93
pubmed: 26138226
Endocr Rev. 2002 Oct;23(5):687-702
pubmed: 12372848
Lancet Infect Dis. 2017 Jan;17(1):39-49
pubmed: 28100438
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2:e50
pubmed: 23836189
Antimicrob Agents Chemother. 2012 Jun;56(6):3232-8
pubmed: 22411614
Expert Rev Clin Pharmacol. 2017 Jan;10(1):47-58
pubmed: 27724114
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
Clin Infect Dis. 2011 May;52(9):e194-9
pubmed: 21467012
Pharmacogenomics. 2018 Jan;19(1):17-29
pubmed: 29210323
Pharmacogenet Genomics. 2014 Mar;24(3):177-83
pubmed: 24492252
Antimicrob Agents Chemother. 2010 Oct;54(10):4192-200
pubmed: 20660695
Int J Evol Biol. 2014;2014:108291
pubmed: 25202468
J Pharmacokinet Biopharm. 1976 Apr;4(2):83-113
pubmed: 950592
Int J Tuberc Lung Dis. 2016 Sep;20(9):1231-5
pubmed: 27510251
Eur J Clin Pharmacol. 2006 Sep;62(9):727-35
pubmed: 16685561
Clin Chem. 2011 Sep;57(9):1303-10
pubmed: 21771946
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28461315
J Antimicrob Chemother. 2017 May 1;72(5):1441-1449
pubmed: 28175315
PLoS One. 2015 Oct 26;10(10):e0141002
pubmed: 26501782
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7
pubmed: 21709081
Tuberculosis (Edinb). 2018 Jan;108:77-82
pubmed: 29523331
Nucleic Acids Res. 2009 Mar;37(4):1160-73
pubmed: 19129222
J Infect Dis. 2011 Dec 15;204(12):1951-9
pubmed: 22021624
Br J Clin Pharmacol. 2011 Jul;72(1):51-62
pubmed: 21320152
J Infect Dev Ctries. 2014 Aug 13;8(8):987-93
pubmed: 25116663
Br J Pharmacol. 2012 Mar;165(5):1260-87
pubmed: 22013971
PLoS Med. 2017 Jan 3;14(1):e1002202
pubmed: 28045934
Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65
pubmed: 25654354
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
Pharmgenomics Pers Med. 2012;5:89-98
pubmed: 23226065
Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13
pubmed: 23629715
Clin Infect Dis. 2017 May 15;64(10):1350-1359
pubmed: 28205671